March 25, 2020 / 1:43 AM / 11 days ago

BRIEF-Immutep Says Secondary Endpoint Of Overall Response Rate Up 48.3% In Efti Group

March 25 (Reuters) - Immutep Ltd:

* 63% OF PATIENTS WHO RECEIVED PACLITAXEL PLUS EFTI WERE PROGRESSION-FREE AT 6-MONTH LANDMARK UNDER AIPAC TRIAL

* SECONDARY ENDPOINT OF OVERALL RESPONSE RATE UP 48.3% IN EFTI GROUP, FROM 38.4% IN PLACEBO GROUP Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below